BMY - Bristol-Myers Squibb Company (BMY) Barclays 26th Annual Global Healthcare Conference (Transcript)
2024-03-14 11:02:09 ET
Bristol-Myers Squibb Company (BMY)
Barclays 26th Annual Global Healthcare Conference
March 14, 2024 08:30 a.m. ET
Company Participants
Lynelle Hoch - President of Cell Therapy
Wendy Short Bartie - Senior Vice President, U.S. Hematology and Oncology
Conference Call Participants
Carter Gould - Barclays
Presentation
Carter Gould
All right. Good morning. Welcome to the Day Three of the Barclays Global Healthcare Conference. I am pleased to welcome Bristol-Myers Squibb to the stage. My name is Carter Gould. I cover U.S. biopharma here. I am pleased to welcome Lynelle Hoch, President of Cell Therapy Organization for Bristol, as well as Wendy Short Bartie, who runs the Hematology and Oncology Business. Welcome both. Thank you very much for joining us today.
A -Lynelle Hoch
Thank you for having us.
Question-and-Answer Session
Q - Carter Gould
Alright, great. So, obviously we’ve got a big day today in terms of the [grantee] (ph) approval, but a big day tomorrow in terms of Abecma outcome. Briefing documents came out yesterday. Maybe we will now just start with sort of your takeaways from the documents. Anything that surprised you in may be your level of confidence at this point?
Lynelle Hoch
Yes. So, as you said, it is a big day and week for Bristol-Myers Squibb overall and certainly in cell therapy. And so, starting with your question specifically around the ODAC, yes, we have had the opportunity to obviously review our briefing book and also on the competitor's briefing book. And I have to say as we thought going into this week and where we sit today, we are extremely confident in the discussion that we will have the FDA. We have been looking forward to this discussion. And if you remember, action date was in December. So, we have been anxiously awaiting the opportunity to defend our data and have a good discussion particularly about the question they have around OS. But just as a reminder, we have already successfully have approval for KarMMa-3 in Japan. We successfully navigated [Augtyro] (ph), which is actually the equivalent of an ODAC for Europe, and that resulted in a positive CHMP nod. And then, also we have had approval in Switzerland....
Bristol-Myers Squibb Company (BMY) Barclays 26th Annual Global Healthcare Conference (Transcript)